Related Experiment Video
Updated: Jun 19, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme
Yuxin Feng1, Yingjie Wang1, Xiaoxue Li2
1Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai 264005, China.
Abstract:
Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator XI-011 analogs were designed, synthesized, and evaluated for their cytotoxic effects. Five compounds (13d, 13e, 14a, 14b, and 14n) exhibited good anti-glioma activity against U87 cells, with IC50 values lower than 2 μM. Notably, 13e showed the best anti-glioma activity, with an IC50 value up to 0.53 μM, providing a promising lead compound for new anti-glioma drug development. Mechanistic analyses showed that 13e suppressed the MDM4 protein expression, upregulated the p53 protein level, and induced cell cycle arrest at G2/M phase and apoptosis based on Western blot and flow cytometry assays.
Insights
Researchers developed novel p53 activator analogs to combat glioblastoma. Compound 13e demonstrated potent anti-glioma activity by inducing cell cycle arrest and apoptosis, offering a promising new drug candidate.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Glioblastoma multiforme is an aggressive brain tumor with limited treatment options.
- Existing therapies face challenges like hematological toxicity and drug resistance.
- There is a critical need for novel anti-glioma drug development.
Purpose of the Study:
- To design, synthesize, and evaluate novel anthracenyl skeleton compounds as p53 activator analogs.
- To identify potent compounds with anti-glioma activity against glioblastoma cells.
- To elucidate the mechanism of action of the most promising compounds.
Main Methods:
- Synthesis of 43 anthracenyl skeleton compounds based on the p53 activator XI-011.
- Cytotoxicity evaluation of synthesized compounds against U87 glioblastoma cells.
- Mechanistic studies including Western blot and flow cytometry to analyze protein expression and cell cycle effects.
Main Results:
- Five compounds (13d, 13e, 14a, 14b, 14n) showed significant anti-glioma activity (IC50 < 2 μM).
- Compound 13e exhibited the highest potency with an IC50 of 0.53 μM.
- Compound 13e suppressed MDM4, upregulated p53, induced G2/M cell cycle arrest, and promoted apoptosis.
Conclusions:
- Novel anthracenyl derivatives show promise as anti-glioma agents.
- Compound 13e is a potential lead compound for glioblastoma drug development.
- The anti-glioma effects of 13e are mediated through p53 activation and induction of apoptosis.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...